141 related articles for article (PubMed ID: 11518468)
1. Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo.
Morris A; Vetto JT; Ramstad T; Funatake CJ; Choolun E; Entwisle C; Weinberg AD
Breast Cancer Res Treat; 2001 May; 67(1):71-80. PubMed ID: 11518468
[TBL] [Abstract][Full Text] [Related]
2. Engagement of the OX-40 receptor in vivo enhances antitumor immunity.
Weinberg AD; Rivera MM; Prell R; Morris A; Ramstad T; Vetto JT; Urba WJ; Alvord G; Bunce C; Shields J
J Immunol; 2000 Feb; 164(4):2160-9. PubMed ID: 10657670
[TBL] [Abstract][Full Text] [Related]
3. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
4. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.
Weinberg AD; Wegmann KW; Funatake C; Whitham RH
J Immunol; 1999 Feb; 162(3):1818-26. PubMed ID: 9973447
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40.
Ramstad T; Lawnicki L; Vetto J; Weinberg A
Am J Surg; 2000 May; 179(5):400-6. PubMed ID: 10930490
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
Kjaergaard J; Tanaka J; Kim JA; Rothchild K; Weinberg A; Shu S
Cancer Res; 2000 Oct; 60(19):5514-21. PubMed ID: 11034096
[TBL] [Abstract][Full Text] [Related]
7. OX-40: life beyond the effector T cell stage.
Weinberg AD; Vella AT; Croft M
Semin Immunol; 1998 Dec; 10(6):471-80. PubMed ID: 9826580
[TBL] [Abstract][Full Text] [Related]
8. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers.
Vetto JT; Lum S; Morris A; Sicotte M; Davis J; Lemon M; Weinberg A
Am J Surg; 1997 Sep; 174(3):258-65. PubMed ID: 9324133
[TBL] [Abstract][Full Text] [Related]
9. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
[TBL] [Abstract][Full Text] [Related]
10. The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells.
Kaleeba JA; Offner H; Vandenbark AA; Lublinski A; Weinberg AD
Int Immunol; 1998 Apr; 10(4):453-61. PubMed ID: 9620601
[TBL] [Abstract][Full Text] [Related]
11. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles.
Brocker T; Gulbranson-Judge A; Flynn S; Riedinger M; Raykundalia C; Lane P
Eur J Immunol; 1999 May; 29(5):1610-6. PubMed ID: 10359115
[TBL] [Abstract][Full Text] [Related]
12. Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response.
Ukyo N; Hori T; Yanagita S; Ishikawa T; Uchiyama T
Immunology; 2003 Jun; 109(2):226-31. PubMed ID: 12757617
[TBL] [Abstract][Full Text] [Related]
13. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.
Akiba H; Miyahira Y; Atsuta M; Takeda K; Nohara C; Futagawa T; Matsuda H; Aoki T; Yagita H; Okumura K
J Exp Med; 2000 Jan; 191(2):375-80. PubMed ID: 10637281
[TBL] [Abstract][Full Text] [Related]
14. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.
Gramaglia I; Weinberg AD; Lemon M; Croft M
J Immunol; 1998 Dec; 161(12):6510-7. PubMed ID: 9862675
[TBL] [Abstract][Full Text] [Related]
15. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
[TBL] [Abstract][Full Text] [Related]
16. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134).
Petty JK; He K; Corless CL; Vetto JT; Weinberg AD
Am J Surg; 2002 May; 183(5):512-8. PubMed ID: 12034383
[TBL] [Abstract][Full Text] [Related]
17. OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines.
Weinberg AD
Trends Immunol; 2002 Feb; 23(2):102-9. PubMed ID: 11929124
[TBL] [Abstract][Full Text] [Related]
18. Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4.
Evans DE; Prell RA; Thalhofer CJ; Hurwitz AA; Weinberg AD
J Immunol; 2001 Dec; 167(12):6804-11. PubMed ID: 11739496
[TBL] [Abstract][Full Text] [Related]
19. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.
Gramaglia I; Jember A; Pippig SD; Weinberg AD; Killeen N; Croft M
J Immunol; 2000 Sep; 165(6):3043-50. PubMed ID: 10975814
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
